We are leading the way in humoral immuno oncology (HIO) by uncovering tumors producing HIO-factors that suppress responses of immune-mediated anti-cancer therapies. We accomplish this by developing diagnostic assays that can identify patients with tumors producing HIO-factors to advise physicians on therapeutic options as well as developing therapeutic agents that can overcome the immuno-suppressive effects of HIO-factors